Logo

Tufts Medical Center

Boston, Massachusetts


About the Center

The Food Allergy Center at Tufts Medical Center in Boston, MA provides integrative, patient-oriented, multidisciplinary and evidence-based care for both adults and children with known or suspected food allergies or food hypersensitivity causing gastrointestinal disorders and other conditions.

We provide care for a number of food allergies and related diseases including:

  • IgE mediated food allergies (e.g. peanut allergy, cow milk allergy and etc)
  • Eosinophilic esophagitis
  • Eosinophilic gastrointestinal disorders
  • Food protein-induced proctitis/colitis and enteropathy of infancy
  • Food protein-induced enterocolitis syndrome (FPIES)
  • Celiac disease
  • Non-celiac gluten hypersensitivity
  • Oral allergy syndrome
  • Food-dependent exercise-induced anaphylaxis
  • Lactose and fructose intolerance
  • Abdominal pain associated with food ingestion
  • Food aversion/phobia

Tufts Medical Center main website
Food Allergy Center at Tufts Medical Center

Related research studies at this Center:
A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Dupilumab in Adult Patients with Active Eosinophilic Esophagitis (Sponsor: Regeneron Pharmaceuticals, Inc.) (NCT02379052)

A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients with Active Eosinophilic Esophagitis (Sponsor: Regeneron Pharmaceuticals)

Fluticasone propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 in Adult and Adolescent Subjects with Eosinophilic Esophagitis (Sponsor: Adare Pharmaceuticals)

A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Safety and Tolerability of AK002 in Patients with Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis (Sponsor: Allakos Inc.)

A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Adult and Adolescent Patients with Active Eosinophilic Esophagitis (Sponsor: Allakos Inc.)

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Patients with Moderately to Severely Active Eosinophilic Gastritis and/or Eosinophilic Duodenitis (formerly referred to as Eosinophilic Gastroenteritis) Who Have an Inadequate Response with, Lost Response to, or Were Intolerant to Standard Therapies (Sponsor: Allakos Inc.)

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab for Eosinophilic Esophagitis (MESSINA) (Sponsor: AstraZeneca)

A Phase 3, Multicenter, Open-label Continuation Study with Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects with Eosinophilic Esophagitis (EoE) (Sponsor: Shire Pharmaceuticals)

Development, Validation and Evaluation of an Adult and Pediatric Eosinophilic Esophagitis Activity Index (Sponsor: University Hospital Inselspital, Berne) (NCT00939263)

Natural History of Eosinophilic Esophagitis

Center Personnel

Tufts Contact Information